ES2745525T3 - Compuestos de aminopiridina sustituida con heteroarilo - Google Patents
Compuestos de aminopiridina sustituida con heteroarilo Download PDFInfo
- Publication number
- ES2745525T3 ES2745525T3 ES16734538T ES16734538T ES2745525T3 ES 2745525 T3 ES2745525 T3 ES 2745525T3 ES 16734538 T ES16734538 T ES 16734538T ES 16734538 T ES16734538 T ES 16734538T ES 2745525 T3 ES2745525 T3 ES 2745525T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridin
- pyrazolo
- carbonitrile
- triazol
- isopropylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN(C1N=C2*)C=NC1C=C2[Rh] Chemical compound CN(C1N=C2*)C=NC1C=C2[Rh] 0.000 description 8
- SGTGXXLTWWAIDL-UHFFFAOYSA-N CC(C)Nc(cc(-[n]1ncc2c1ncc(C#N)c2)nc1)c1-c1c[n](CC(F)(F)F)nc1 Chemical compound CC(C)Nc(cc(-[n]1ncc2c1ncc(C#N)c2)nc1)c1-c1c[n](CC(F)(F)F)nc1 SGTGXXLTWWAIDL-UHFFFAOYSA-N 0.000 description 1
- WRWNPDTZJNLWHL-UHFFFAOYSA-N CC(C)Nc(cc(-[n]1ncc2c1ncc(C#N)c2)nc1)c1-c1cc(C2CNC2)n[o]1 Chemical compound CC(C)Nc(cc(-[n]1ncc2c1ncc(C#N)c2)nc1)c1-c1cc(C2CNC2)n[o]1 WRWNPDTZJNLWHL-UHFFFAOYSA-N 0.000 description 1
- SWRKUPLIPIEAOS-UHFFFAOYSA-N CC(C)Nc(cc(-[n]1ncc2cc(C#N)cnc12)nc1)c1-[n]1nnc(C2CCN(CC(F)F)CC2)c1 Chemical compound CC(C)Nc(cc(-[n]1ncc2cc(C#N)cnc12)nc1)c1-[n]1nnc(C2CCN(CC(F)F)CC2)c1 SWRKUPLIPIEAOS-UHFFFAOYSA-N 0.000 description 1
- CPLQNQBMMGLAAJ-UHFFFAOYSA-N CC(C)Nc(cc(-[n]1ncc2cc(C#N)cnc12)nc1)c1-[n]1nnc(C2CCNCC2)c1 Chemical compound CC(C)Nc(cc(-[n]1ncc2cc(C#N)cnc12)nc1)c1-[n]1nnc(C2CCNCC2)c1 CPLQNQBMMGLAAJ-UHFFFAOYSA-N 0.000 description 1
- GVPHIPBSKCVWBA-DLBZAZTESA-N CC(C)Nc(cc(nc1)Cl)c1-c1c[n]([C@@H](CCN(C2)C(OC(C)(C)C)=O)[C@@H]2O)nn1 Chemical compound CC(C)Nc(cc(nc1)Cl)c1-c1c[n]([C@@H](CCN(C2)C(OC(C)(C)C)=O)[C@@H]2O)nn1 GVPHIPBSKCVWBA-DLBZAZTESA-N 0.000 description 1
- CNAUUJIWAQALDJ-UHFFFAOYSA-N CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1c[n](C(C2)CN2C(C)C)nn1 Chemical compound CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1c[n](C(C2)CN2C(C)C)nn1 CNAUUJIWAQALDJ-UHFFFAOYSA-N 0.000 description 1
- HIUCJCFXTWGEIE-UHFFFAOYSA-N CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1c[n](C(C2)CN2C(CC2CC2)=O)nn1 Chemical compound CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1c[n](C(C2)CN2C(CC2CC2)=O)nn1 HIUCJCFXTWGEIE-UHFFFAOYSA-N 0.000 description 1
- JMLWLLVDDWTHOR-UHFFFAOYSA-N CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1cc(C(C2)CN2C(C)=O)n[o]1 Chemical compound CC(C)Nc1cc(-[n]2ncc3c2ncc(C#N)c3)ncc1-c1cc(C(C2)CN2C(C)=O)n[o]1 JMLWLLVDDWTHOR-UHFFFAOYSA-N 0.000 description 1
- BFKKIDHWWRDAPL-UHFFFAOYSA-N CC(C)Nc1cc(-[n]2ncc3cc(C#N)cnc23)ncc1-c1c[n](C(C2)CN2c2nnc(C)[o]2)nn1 Chemical compound CC(C)Nc1cc(-[n]2ncc3cc(C#N)cnc23)ncc1-c1c[n](C(C2)CN2c2nnc(C)[o]2)nn1 BFKKIDHWWRDAPL-UHFFFAOYSA-N 0.000 description 1
- ZRJCNMYMCUBLAI-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1-c1c[nH]nc1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1c[nH]nc1 ZRJCNMYMCUBLAI-UHFFFAOYSA-N 0.000 description 1
- QGSSQOPZQYGFHL-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1-c1c[n](CC(C)F)nn1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1c[n](CC(C)F)nn1 QGSSQOPZQYGFHL-UHFFFAOYSA-N 0.000 description 1
- UMBXYHRYEHEXSL-SFHVURJKSA-N CC(C)Nc1cc(Cl)ncc1-c1c[n](C[C@H](Cc2ccccc2)NC(OC(C)(C)C)=O)nn1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1c[n](C[C@H](Cc2ccccc2)NC(OC(C)(C)C)=O)nn1 UMBXYHRYEHEXSL-SFHVURJKSA-N 0.000 description 1
- JNDCZWRSJRYUDD-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1-c1nnc(C(N(CC2)CCN2C(OC(C)(C)C)=O)=O)[o]1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1nnc(C(N(CC2)CCN2C(OC(C)(C)C)=O)=O)[o]1 JNDCZWRSJRYUDD-UHFFFAOYSA-N 0.000 description 1
- IMFLIGANAFVVEX-UHFFFAOYSA-O CC(C)Nc1cc(Cl)ncc1C(N=N)=C[NH2+]CC(C)F Chemical compound CC(C)Nc1cc(Cl)ncc1C(N=N)=C[NH2+]CC(C)F IMFLIGANAFVVEX-UHFFFAOYSA-O 0.000 description 1
- GTVJTOUCOLLRGC-UHFFFAOYSA-N CC(C)[n]1ncc(O)c1 Chemical compound CC(C)[n]1ncc(O)c1 GTVJTOUCOLLRGC-UHFFFAOYSA-N 0.000 description 1
- JANHZYJACYIJQP-UHFFFAOYSA-N CCCN1C=NC2C=NC([Rh])=NC12 Chemical compound CCCN1C=NC2C=NC([Rh])=NC12 JANHZYJACYIJQP-UHFFFAOYSA-N 0.000 description 1
- NOEFIUWJGDCTGB-UHFFFAOYSA-N CCOC(c(c(NC(C)C)c1)cnc1-[n](cc1)c2c1cncn2)=O Chemical compound CCOC(c(c(NC(C)C)c1)cnc1-[n](cc1)c2c1cncn2)=O NOEFIUWJGDCTGB-UHFFFAOYSA-N 0.000 description 1
- BLHTXORQJNCSII-UHFFFAOYSA-N Cc1c[n](C)cn1 Chemical compound Cc1c[n](C)cn1 BLHTXORQJNCSII-UHFFFAOYSA-N 0.000 description 1
- SZQCPPRPWDXLMM-UHFFFAOYSA-N Cc1c[n](C)nc1 Chemical compound Cc1c[n](C)nc1 SZQCPPRPWDXLMM-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- ZOEPGDLOKCFSAJ-WOJBJXKFSA-N N#Cc1cc(cn[n]2-c(nc3)cc(NC4CC4)c3-c3c[n]([C@H](CNCC4)[C@@H]4O)nn3)c2nc1 Chemical compound N#Cc1cc(cn[n]2-c(nc3)cc(NC4CC4)c3-c3c[n]([C@H](CNCC4)[C@@H]4O)nn3)c2nc1 ZOEPGDLOKCFSAJ-WOJBJXKFSA-N 0.000 description 1
- DEJUUKULVAIMNF-UHFFFAOYSA-N Nc1cc(Cl)ncc1I Chemical compound Nc1cc(Cl)ncc1I DEJUUKULVAIMNF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1877DE2015 | 2015-06-24 | ||
| PCT/US2016/038858 WO2016210034A1 (en) | 2015-06-24 | 2016-06-23 | Heteroaryl substituted aminopyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2745525T3 true ES2745525T3 (es) | 2020-03-02 |
Family
ID=56322320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16734538T Active ES2745525T3 (es) | 2015-06-24 | 2016-06-23 | Compuestos de aminopiridina sustituida con heteroarilo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10294229B2 (https=) |
| EP (1) | EP3313840B1 (https=) |
| JP (1) | JP6843775B2 (https=) |
| CN (1) | CN107849039B (https=) |
| AR (1) | AR105113A1 (https=) |
| ES (1) | ES2745525T3 (https=) |
| TW (1) | TW201718571A (https=) |
| UY (1) | UY36748A (https=) |
| WO (1) | WO2016210034A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| EP3848370B1 (en) * | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| PE20191817A1 (es) | 2017-05-11 | 2019-12-27 | Bristol Myers Squibb Co | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| TWI812649B (zh) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| WO2020036830A1 (en) | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| CN112566697B (zh) | 2018-08-13 | 2024-04-16 | 吉利德科学公司 | 作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN109836376B (zh) * | 2019-04-10 | 2022-03-22 | 江苏汉阔生物有限公司 | 一种以2，3-吡啶二羧酸为原料制备2-氯代烟酸的方法 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3999508B1 (en) | 2019-07-18 | 2023-08-30 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| CN114127075B (zh) | 2019-07-18 | 2024-05-14 | 百时美施贵宝公司 | 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物 |
| JP7573596B2 (ja) * | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| WO2021026181A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| ES3059914T3 (en) | 2019-08-13 | 2026-03-24 | Bristol Myers Squibb Co | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021067967A1 (en) * | 2019-10-04 | 2021-04-08 | University Of Kentucky Research Foundation | Preparation of pyrazolo[3,4-b]pyridines as antimalarials |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4077286A1 (en) | 2019-12-18 | 2022-10-26 | Elanco Tiergesundheit AG | Isoxazoline derivatives as pesticides |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| EP4107158A1 (en) * | 2020-02-19 | 2022-12-28 | Nurix Therapeutics, Inc. | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| PH12023500015A1 (en) * | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| AU2003244098A1 (en) | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR20100020454A (ko) | 2007-06-08 | 2010-02-22 | 바이엘 크롭사이언스 소시에떼아노님 | 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JPWO2010058846A1 (ja) | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| WO2010061971A1 (ja) | 2008-11-28 | 2010-06-03 | 興和株式会社 | ピリジン－３－カルボキシアミド誘導体 |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| CN103619854A (zh) | 2011-04-29 | 2014-03-05 | 西奈山伊坎医学院 | 激酶抑制剂 |
| EP2802576B1 (en) * | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104254533B (zh) | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9315494B2 (en) | 2012-11-08 | 2016-04-19 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
-
2016
- 2016-06-23 TW TW105119777A patent/TW201718571A/zh unknown
- 2016-06-23 EP EP16734538.8A patent/EP3313840B1/en active Active
- 2016-06-23 US US15/738,362 patent/US10294229B2/en active Active
- 2016-06-23 ES ES16734538T patent/ES2745525T3/es active Active
- 2016-06-23 CN CN201680040987.7A patent/CN107849039B/zh active Active
- 2016-06-23 WO PCT/US2016/038858 patent/WO2016210034A1/en not_active Ceased
- 2016-06-23 AR ARP160101892A patent/AR105113A1/es unknown
- 2016-06-23 JP JP2017566643A patent/JP6843775B2/ja active Active
- 2016-06-23 UY UY0001036748A patent/UY36748A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20180186799A1 (en) | 2018-07-05 |
| JP6843775B2 (ja) | 2021-03-17 |
| WO2016210034A1 (en) | 2016-12-29 |
| UY36748A (es) | 2016-12-30 |
| AR105113A1 (es) | 2017-09-06 |
| CN107849039A (zh) | 2018-03-27 |
| JP2018522859A (ja) | 2018-08-16 |
| TW201718571A (zh) | 2017-06-01 |
| CN107849039B (zh) | 2020-07-03 |
| EP3313840A1 (en) | 2018-05-02 |
| US10294229B2 (en) | 2019-05-21 |
| EP3313840B1 (en) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2745525T3 (es) | Compuestos de aminopiridina sustituida con heteroarilo | |
| US12247027B2 (en) | P2X7 modulators | |
| ES2804707T3 (es) | Compuestos de nicotinamida sustituidos con heteroarilo | |
| ES2822956T3 (es) | Compuestos de aminopiridina sustituidos con heteroarilo | |
| ES2783852T3 (es) | Compuestos de aminopiridina sustituidos con heteroarilo | |
| CN110612298A (zh) | 用作irak4抑制剂的噻吩并吡啶及苯并噻吩化合物 | |
| BR112018074621B1 (pt) | compostos derivados de pirazolopirimidina como inibidores de quinase, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
| CN114206874B (zh) | 可用作irak4抑制剂的双环杂芳基化合物 | |
| ES2960521T3 (es) | Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4 | |
| ES3036306T3 (en) | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors | |
| ES2977339T3 (es) | Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4 |